Development and validation of a next-generation sequencing assay with open-access analysis software for detecting resistance-associated mutations in CMV
- 19 December 2023
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 61 (12) , e0082923
Abstract
Cytomegalovirus (CMV) resistance testing by targeted next-generation sequencing (NGS) allows for the simultaneous analysis of multiple genes. We developed and validated an amplicon-based Ion Torrent NGS assay to detect CMV resistance mutations in UL27, UL54, UL56, and UL97 and compared the results to standard Sanger sequencing. NGS primers were designed to generate 83 overlapping amplicons of four CMV genes (~10 kb encompassing 138 mutation sites). An open-access software plugin was developed to perform read alignment, call variants, and interpret drug resistance. Plasmids were tested to determine NGS error rate and minor variant limit of detection. NGS limit of detection was determined using the CMV WHO International Standard and quantified clinical specimens. Reproducibility was also assessed. After establishing quality control metrics, 185 patient specimens previously tested using Sanger were reanalyzed by NGS. The NGS assay had a low error rate (<0.05%) and high accuracy (95%) for detecting CMV-associated resistance mutations present at ≥5% in contrived mixed populations. Mutation sites were reproducibly sequenced with 40× coverage when plasma viral loads were ≥2.6 log IU/mL. NGS detected the same resistance-associated mutations identified by Sanger in 68/69 (98.6%) specimens. In 16 specimens, NGS detected 18 resistance mutations that Sanger failed to detect; 14 were low-frequency variants (<20%), and six would have changed the drug resistance interpretation. The NGS assay showed excellent agreement with Sanger and generated high-quality sequence from low viral load specimens. Additionally, the higher resolution and analytic sensitivity of NGS potentially enables earlier detection of antiviral resistance.Keywords
Funding Information
- ARUP Institute for Clinical and Experimental Pathology
This publication has 33 references indexed in Scilit:
- Improved Detection of Emerging Drug-Resistant Mutant Cytomegalovirus Subpopulations by Deep SequencingAntimicrobial Agents and Chemotherapy, 2014
- Cytomegalovirus antiviral resistance: characterization of results from clinical specimensTransplant Infectious Disease, 2014
- Resistance of human cytomegalovirus to ganciclovir/valganciclovir: A comprehensive review of putative resistance pathwaysAntiviral Research, 2014
- Detection of Cytomegalovirus Drug Resistance Mutations by Next-Generation SequencingJournal of Clinical Microbiology, 2013
- LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasetsNucleic Acids Research, 2012
- Antiviral Drug Resistance of Human CytomegalovirusClinical Microbiology Reviews, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under MaribavirAntimicrobial Agents and Chemotherapy, 2009
- Mutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to MaribavirJournal of Virology, 2004
- Sources and Magnitude of Intralaboratory Variability in a Sequence-Based Genotypic Assay for Human Immunodeficiency Virus Type 1 Drug ResistanceJournal of Clinical Microbiology, 2003